2-chlorodeoxyadenosine

DRUG2 trials

Sponsors

North American Consortium for Histiocytosis, Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Conditions

Langerhans Cell Histiocytosis

Phase 2

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Active, not recruitingNCT02205762

North American Consortium for HistiocytosisLangerhans Cell Histiocytosis

Start: 2016-11-02End: 2026-07-01Updated: 2026-04-09

A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyLangerhans Cell Histiocytosis

Start: 2018-06-26End: 2023-12-31Target: 12Updated: 2023-03-16

Related Papers

The results of a study on the effectiveness 37 and safety of treatment with vemurafenib and cytarabine/2-chloro-2′-deoxyadenosine combination in patients with Langerhans cell histiocytosis with <i>BRAFV600E</i> mutation

Pediatric Hematology/Oncology and Immunopathology2023-10-17

Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH

Blood Advances2023-05-2224 citations

Dabrafenib, alone or in combination with trametinib, in <i>BRAF</i> V600–mutated pediatric Langerhans cell histiocytosis

Blood Advances2023-03-0845 citations